Clinical Trial Update: A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 trial update examining the effect of LY2140023 (pomaglumetad methionil) on ECGs in participants with schizophrenia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• LY2140023

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenic Disorders | Phase 1 | Status: COMPLETED | Results posted: 2023-04-03